不同铂类药物联合调强放疗治疗中晚期NSCLC患者的血清肿瘤标志物水平及疗效观察  

The Effect of Two Platinum Drugs Combined with Intensity Modulated Radiotherapy on Serum Tumor Markers and Clinical Efficacy for Patients with Advanced NSCLC Level

作　　者：节阳华[1] 朱艳华[2] 曾凡业[2] 马全海 王宁[1] JIE Yanghua;ZHU Yanhua;ZENG Fanye;MA Quanhai;WANG Ning(Deparlment of Radiotherapy;Deparlment of Oncology, Affiliated Traditional Hospital Xinjiang Medical University, Unum-chi, Xinjiang, 830000, China)

机构地区：[1]新疆医科大学附属中医医院放疗科,新疆乌鲁木齐830000 [2]新疆医科大学附属中医医院肿瘤科,新疆乌鲁木齐830000

出　　处：《肿瘤药学》2018年第2期263-267,共5页Anti-Tumor Pharmacy

基　　金：新疆自治区自然基金(2012211A094)

摘　　要：目的比较奈达铂与顺铂联合调强放疗治疗中晚期NSCLC的血清肿瘤标志物水平及疗效差异。方法选取在我院肿瘤放疗科住院的118例中晚期NSCLC患者作为研究对象,随机分为A组(奈达铂,59例)和B组(顺铂,59例),分别联合调强放疗方案,比较两组患者血清肿瘤标志物水平、临床疗效、毒副反应和生存率的差异。结果 A、B两组患者总有效率分别为89.83%和81.36%,治疗后生活质量显著改善,但组间差异无统计学意义(P>0.05)。治疗后,两组CAE、SCC-Ag、CYFRA21-1、TK1水平与治疗前相比均显著降低(P<0.05),A组SCC-Ag和TK1水平显著低于B组(P<0.05)。A组恶心、呕吐以及肾功能损害发生率显著低于B组(P<0.05)。结论奈达铂治疗中晚期NSCLC的疗效与顺铂相当,且肿瘤标志物水平较低,毒副反应小,患者耐受性高。Objective To study the effects of different platinum chemotherapy regimens combined with intensity modulated radiotherapy on the serum tumor marker levels and efficacy for advanced non-small cell lung cancer （NSCLC） patients. Methods A total of 118 patients with advanced NSCLC lung cancer were enrolled in department of oncology and radiotherapy in our hospital. They were randomly divided into group A and group B, 59 cases for each group. The patients in group A were given nedaplatin combined with intensity modulated ra-diotherapy, and those in group B were given cisplatin combined with three dimensional conformal radiotherapy. The levels of serum tumor markers, clinical efficacy, differences in toxicity and survival rate were compared between the two groups. Results The total effective rates of patients in group A and B were 89.83% and 81.36% respectively. The quality of life was significantly improved in the two groups after treat-ment, but it had no significant difference between the two groups （P〉0.05）. After treatment, the levels of CAE, SCC-Ag, CYFRA21-1 and TK1 in the two groups were decreased significantly compared with those before treatment （P〈0.05）. After treatment, the levels of SCC-A and TK1 of patients in group A were significantly lower than in group B （P〈0.05）. The incidences of side reactions like nausea, vomiting and renal impairment in group A was significantly lower than in group B, and it had statistical differences between the two groups （P〈0.05）. Conclusion Nedaplatin had equivalent efficacy to cisplatin in the treatment of patients with late NSCLC. It also had lower levels of tumor markers of patients and lower incidences of toxicity and side effects. So the patients in nedaplatin group were highly tolerated.

关 键 词：非小细胞肺癌 调强放疗 奈达铂 肿瘤标志物 

分 类 号：R734.2[医药卫生—肿瘤]